Status:
RECRUITING
Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With Endovascular Therapy (INSIST-ET)
Lead Sponsor:
Hui-Sheng Chen
Conditions:
Stroke, Ischemic
Intravascular Thrombosis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
To explore the safety and feasibility of intra-arterial neuroprotective strategy in acute ischemic stroke patients who received recanalization operation.
Eligibility Criteria
Inclusion
- Age ≥18 years;
- Acute ischemic stroke patients who is eligible for endovascular treatment;
- Signed informed consent.
Exclusion
- Modified Rankin Score \>2 caused by a history of prior stroke;
- Coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia (\<80000/mm3);
- Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis;
- Severe hypertension (systolic blood pressure over 200mmHg or diastolic blood pressure over 110 mmHg);
- Unsuitable for this clinical studies assessed by researcher.
Key Trial Info
Start Date :
December 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 31 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04664933
Start Date
December 1 2020
End Date
May 31 2026
Last Update
August 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Neurology, General Hospital of Northern Theater Command
Shenyang, China, 110016